Novo Nordisk stock news
Novo Nordisk (NVO) has formalized a clinical supply agreement with Veru Inc., as disclosed in a June 4, 2026, SEC filing. The company will supply Wegovy at no cost for Veru's Phase 2b PLATEAU trial, which investigates the combination of enobosarm and semaglutide for muscle preservation during weight loss in older adults. Critically, Novo Nordisk secured a right of first negotiation for future commercialization of the combination therapy. This move strategically positions Novo Nordisk to lead in the next generation of 'high--quality' weight loss treatments that address lean muscle mass retention.